Stephanie Wade
Family · Palmdale, CANPI 1396942736
Payments from drug & device makers
Across 41 payments — averaging $25.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mayne Pharma Commercial LLC$179
- AbbVie$123
- Astellas Pharma US Inc$102
- Lilly USA, LLC$83
- Dexcom, Inc.$81
- Merck$68
- plus $408 from 16 others
What the payments were for
- Food & beverage$1,044100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mayne Pharma Commercial LLC | 1 | $179 |
| AbbVie | 6 | $123 |
| Astellas Pharma US Inc | 4 | $102 |
| Lilly USA, LLC | 4 | $83 |
| Dexcom, Inc. | 2 | $81 |
| Merck | 3 | $68 |
| Amgen(2 entities) | 3 | $61 |
| Novo Nordisk | 2 | $44 |
| Shield Therapeutics Inc | 2 | $39 |
| AstraZeneca | 2 | $36 |
| Tempus AI, Inc | 1 | $24 |
| Corium, LLC | 1 | $23 |
| Avion Pharmaceuticals | 1 | $21 |
| Ascensia Diabetes Care US Inc. | 1 | $21 |
| Phadia US Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $19 |
| GSK | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Medtronic | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
How this compares
$1,044 in reported general payments places this provider in the 75th percentile of 10,634 family providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Norethindrone Acetate | 17 | $784 |
| YuvafemEstradiol | 13 | $736 |
| Olmesartan Medoxomil | 18 | $299 |
| Rosuvastatin Calcium | 16 | $165 |
| Gabapentin | 26 | $151 |
| Escitalopram Oxalate | 12 | $150 |
| Levothyroxine Sodium | 19 | $137 |
| Montelukast Sodium | 14 | $113 |
| Indapamide | 13 | $66 |
| Amlodipine Besylate | 12 | $57 |
| Hydrochlorothiazide | 20 | $11 |
Paid to pharmacies, not to this prescriber.
Other family in Palmdale
- So-Young KimPalmdale$98K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.